Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Peijia Medical Ltd. ( (HK:9996) ) is now available.
Peijia Medical Ltd. announced significant revenue growth for the year ended December 31, 2024, driven by their neurointerventional product lines and expanded presence in the Chinese TAVR market. The company achieved major milestones with the successful launch and market adoption of DCwire® Micro Guidewire and further market penetration of Syphonet® Stent Retriever and Fastunnel® Delivery Balloon Dilatation Catheter. Additionally, Peijia Medical’s TAVR products, TaurusOne® and TaurusElite®, have been adopted by over 150 new hospitals, highlighting their effective market education and development strategies.
More about Peijia Medical Ltd.
Peijia Medical Ltd. is a company incorporated in the Cayman Islands focusing on the medical industry, specifically in the development and sales of neurointerventional products and transcatheter aortic valve replacement (TAVR) devices. Their primary products include devices for hemorrhagic, ischemic, and vascular access procedures, with a strong market focus on expanding their share in the Chinese medical device market.
YTD Price Performance: -9.17%
Average Trading Volume: 277
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €309.4M
Find detailed analytics on 9996 stock on TipRanks’ Stock Analysis page.
